pentoxifylline has been researched along with Kidney Neoplasms in 11 studies
Kidney Neoplasms: Tumors or cancers of the KIDNEY.
| Excerpt | Relevance | Reference |
|---|---|---|
| " pentoxifylline (Px) (which also were found to release PgI2 and t-PA) inhibited human tumor implant induced angiogenesis and reduced spontaneous metastases in 3 transplantable murine tumors (Furth-Columbia Wilms' tumor in Furth-Wistar rats, C-1300 neuroblastoma in A/J mice and HM-Kim mammary carcinoma in Wistar rats) but not in the NIH adenocarcinoma in Balb/c mice." | 3.68 | Studies on tumor induced angiogenesis. ( Ambrus, CM; Ambrus, JL; Forgach, P; Halpern, J; Niswander, P; Sayyid, S; Stadler, S; Toumbis, C, 1992) |
| "Patients with disseminated renal cell carcinoma were treated with continuous infusion of 18 x 10(6) IU/m2/24 h for 4 days followed by 3 days without treatment, for 4 consecutive weeks." | 2.68 | The effects of oral pentoxifylline on interleukin-2 toxicity in patients with metastatic renal cell carcinoma. ( Anderson, JA; Edwards, MJ; Harty, JI; Knott, AW; Woodcock, TM, 1995) |
| "Pentoxifylline (PTX) is a methylxanthine which reduces IL-2 toxicity in animals." | 2.67 | Phase Ib trial of pentoxifylline and ciprofloxacin in patients treated with interleukin-2 and lymphokine-activated killer cell therapy for metastatic renal cell carcinoma. ( Benyunes, MC; Bianco, JA; Fefer, A; Neubauer, MA; Slattery, JT; Thompson, JA, 1994) |
| " When PTX was used in combination with TNF-alpha, the level of TNF-alpha mRNA induced by TNF-alpha was markedly reduced." | 1.29 | Overcoming TNF-alpha and drug resistance of human renal cell carcinoma cells by treatment with pentoxifylline in combination with TNF-alpha or drugs: the role of TNF-alpha mRNA downregulation in tumor cell sensitization. ( Bonavida, B; Mizutani, Y; Nio, Y; Yoshida, O, 1994) |
| "Pentoxifylline (PTX) is a methylated xanthine that has been shown to reduce the toxicity of Interleukin-2 (IL-2) therapy in animal models, possibly by inhibiting secretion of tumor necrosis factor-alpha." | 1.29 | The effects of pentoxifylline on the generation of human lymphokine-activated killer cell cytotoxicity. ( Benyunes, MC; Bianco, JA; Fefer, A; Lindgren, CG; Shields, AF; Thompson, JA, 1993) |
| "Treatment of patients with metastatic renal cell carcinoma with high-dose interleukin-2 (IL-2) administered as continuous intravenous (CIV) infusion or as bolus injection results in response rates of 15% to 30%; however, toxicities with these regimens have been severe." | 1.29 | High-dose continuous intravenous infusion of interleukin-2 therapy for metastatic renal cell carcinoma: the University of Chicago experience. ( Shulman, KL; Stadler, WM; Vogelzang, NJ, 1996) |
| " In the present experiment pentoxifylline appears to be a highly effective platelet aggregation inhibitor: a dose-response curve is apparent in monkey between 6 and 24 mg/kg i." | 1.26 | Effect of phosphodiesterase inhibitors on platelet aggregation and tumor metastasis. ( Ambrus, CM; Ambrus, JL; Gastpar, H, 1981) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 1 (9.09) | 18.7374 |
| 1990's | 9 (81.82) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (9.09) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Cohen, JD | 1 |
| Tham, KY | 1 |
| Mastrandrea, NJ | 1 |
| Gallegos, AC | 1 |
| Monks, TJ | 1 |
| Lau, SS | 1 |
| Ambrus, JL | 2 |
| Ambrus, CM | 2 |
| Gastpar, H | 1 |
| Anderson, JA | 1 |
| Woodcock, TM | 1 |
| Harty, JI | 1 |
| Knott, AW | 1 |
| Edwards, MJ | 1 |
| Thompson, JA | 3 |
| Bianco, JA | 3 |
| Benyunes, MC | 3 |
| Neubauer, MA | 1 |
| Slattery, JT | 1 |
| Fefer, A | 3 |
| Mizutani, Y | 1 |
| Bonavida, B | 1 |
| Nio, Y | 1 |
| Yoshida, O | 1 |
| Lindgren, CG | 1 |
| Shields, AF | 1 |
| Shulman, KL | 1 |
| Stadler, WM | 2 |
| Vogelzang, NJ | 2 |
| Rini, BI | 1 |
| Spielberger, RT | 1 |
| Ratain, MJ | 1 |
| Margolin, K | 1 |
| Atkins, M | 1 |
| Sparano, J | 1 |
| Sosman, J | 1 |
| Weiss, G | 1 |
| Lotze, M | 1 |
| Doroshow, J | 1 |
| Mier, J | 1 |
| O'Boyle, K | 1 |
| Fisher, R | 1 |
| Campbell, E | 1 |
| Rubin, J | 1 |
| Federighi, D | 1 |
| Bursten, S | 1 |
| Forgach, P | 1 |
| Stadler, S | 1 |
| Halpern, J | 1 |
| Sayyid, S | 1 |
| Niswander, P | 1 |
| Toumbis, C | 1 |
1 review available for pentoxifylline and Kidney Neoplasms
| Article | Year |
|---|---|
Treatment with pentoxifylline and ciprofloxacin reduces the toxicity of high-dose interleukin-2 and lymphokine-activated killer cells.
Topics: Carcinoma, Renal Cell; Ciprofloxacin; Clinical Trials as Topic; Drug Therapy, Combination; Humans; I | 1993 |
4 trials available for pentoxifylline and Kidney Neoplasms
| Article | Year |
|---|---|
The effects of oral pentoxifylline on interleukin-2 toxicity in patients with metastatic renal cell carcinoma.
Topics: Administration, Oral; Carcinoma, Renal Cell; Humans; Interleukin-2; Kidney Neoplasms; Nausea; Pentox | 1995 |
Phase Ib trial of pentoxifylline and ciprofloxacin in patients treated with interleukin-2 and lymphokine-activated killer cell therapy for metastatic renal cell carcinoma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Renal Cell; Ciprofloxacin; F | 1994 |
Granulocyte-macrophage--colony stimulating factor in metastatic renal cell carcinoma: a phase II trial.
Topics: Adult; Aged; Carcinoma, Renal Cell; Female; Granulocyte-Macrophage Colony-Stimulating Factor; Humans | 1998 |
Prospective randomized trial of lisofylline for the prevention of toxicities of high-dose interleukin 2 therapy in advanced renal cancer and malignant melanoma.
Topics: Adult; Aged; Anti-Inflammatory Agents, Non-Steroidal; Creatinine; Dose-Response Relationship, Drug; | 1997 |
6 other studies available for pentoxifylline and Kidney Neoplasms
| Article | Year |
|---|---|
cAMP-dependent cytosolic mislocalization of p27(kip)-cyclin D1 during quinol-thioether-induced tuberous sclerosis renal cell carcinoma.
Topics: Animals; Benzenesulfonates; Bucladesine; Carcinoma, Renal Cell; Cell Line; Cyclin D1; Cyclin-Depende | 2011 |
Effect of phosphodiesterase inhibitors on platelet aggregation and tumor metastasis.
Topics: Adenocarcinoma; Adenosine Diphosphate; Animals; Carcinoma, Ehrlich Tumor; Female; Head and Neck Neop | 1981 |
Overcoming TNF-alpha and drug resistance of human renal cell carcinoma cells by treatment with pentoxifylline in combination with TNF-alpha or drugs: the role of TNF-alpha mRNA downregulation in tumor cell sensitization.
Topics: Carcinoma, Renal Cell; Cisplatin; Down-Regulation; Drug Resistance; Drug Therapy, Combination; Human | 1994 |
The effects of pentoxifylline on the generation of human lymphokine-activated killer cell cytotoxicity.
Topics: Administration, Oral; Carcinoma, Renal Cell; Cytotoxicity, Immunologic; Humans; Immunologic Factors; | 1993 |
High-dose continuous intravenous infusion of interleukin-2 therapy for metastatic renal cell carcinoma: the University of Chicago experience.
Topics: Adjuvants, Immunologic; Adult; Aged; Carcinoma, Renal Cell; Drug Therapy, Combination; Female; Human | 1996 |
Studies on tumor induced angiogenesis.
Topics: Adenocarcinoma; Aminocaproic Acid; Animals; Cornea; Ditiocarb; Humans; Kidney Neoplasms; Macaca; Mam | 1992 |